Twins Study of Gene Therapy for HIV Infection

Inclusion Criteria

• •An identical twin pair, one of whom is seropositive for HIV-1, the other twin seronegative, by standard ELISA and Western blot testing.
• •Patients with Kaposi's sarcoma limited to the skin and/or mucous membranes are eligible for this study, but must not have received any systemic therapy for
• •KS within 4 weeks prior to entry. The diagnosis of KS must have been confirmed by biopsy.
• •Free from serious psychological or emotional illness and able to provide written informed consent.
• •Anticipated survival greater than 3 months.
• •18 years of age or older.
• •Treatment with FDA-approved and/or expanded access antiretroviral agent(s) for patients with baseline CD4 counts below 500 cells/mm(3). Patients with baseline CD4 counts above 500 cells/mm(3) are eligible to receive cell therapy on this protocol, but must be treated with antiretroviral therapy if evidence of significant and persistent viral activation occurs in association with a cell infusion. "Significant and persistent viral activation" is defined as a 50 percent or greater increase above baseline in any virologic parameter for at least 2 consecutive weeks.
• •Recipient's CD4 count greater than 50 cells/mm(3).
• •Recipient and Donor willing to have samples stored and undergo HLA testing.